TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24550190

Group type: COMPARATOR
Intervention: AG (1 µg/kg/h)
Number of subjects: 17

Group type: COMPARATOR
Intervention: AG+UAG
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: UAG (4 µg/kg/h)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: AG
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: UAG
Number of subjects: 17
Study: 23061628

Group type: EXPERIMENTAL
Intervention: Infliximab (5mg/kg in a single intravenous infusion)
Number of subjects: 14
Study: 19545556

Group type: EXPERIMENTAL
Intervention: Mean telomere repeat copy number to single gene copy number (T/S ratio) in cases (VTE)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Mean telomere repeat copy number to single gene copy number (T/S ratio) in controls
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Multi-variable adjusted analysis of T/S ratios
Number of subjects: 216
Study: 17314192

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS (120% of motor threshold; 1200 stimuli/day for 5 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 16
Study: 15064593

Group type: EXPERIMENTAL
Intervention: Supervised Tai Chi for 1.5 h, 6x wk for 8 wk
Number of subjects: 49
Study: 11759263

Group type: EXPERIMENTAL
Intervention: Validation group (n = 100)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Cross-validation group (n = 54)
Number of subjects: 154
Study: 9773697

Group type: COMPARATOR
Intervention: Intrathecal sufentanil 2, 5, or 10 microg (2 mL volume) and epidural saline (10 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Epidural bupivacaine 5, 12.5, or 25 mg and intrathecal saline (2 mL volume)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of intrathecal sufentanil (1, 2.5, and 5 microg) plus epidural bupivacaine (2.5, 6.25, or 12.5 mg)
Number of subjects: 100
Study: 7828395

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (15 ml of potassium chloride with 0.9 mmol K per ml, three times a day) in group 2 (72 patients on diuretics)
Number of subjects: 320

Group type: COMPARATOR
Intervention: 2-day preparation of 15 g magnesium sulphate and 10 mg bisacodyl twice daily in group 1 (55 patients on diuretics without potassium supplements)
Number of subjects: 320

Group type: COMPARATOR
Intervention: 2-day preparation of 15 g magnesium sulphate and 10 mg bisacodyl twice daily in group 3 (97 patients)
Number of subjects: 320

Group type: COMPARATOR
Intervention: 1-day preparation of 2.4 mg sennoside per kg in group 4 (96 patients)
Number of subjects: 320
Study: 3338014

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with chlorambucil for 2 years
Number of subjects: 162

Group type: COMPARATOR
Intervention: Follow-up alone
Number of subjects: 162
Study: 2149806

Group type: EXPERIMENTAL
Intervention: Gestodene preparation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Desogestrel preparation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study: 788625

Group type: EXPERIMENTAL
Intervention: Dixyrazine
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 31651350

Group type: EXPERIMENTAL
Intervention: 8.25 mg dexamethasone intravenously after 8 hours of hypoxia with an FiO2 of 12%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline placebo intravenously after 8 hours of hypoxia with an FiO2 of 12%
Number of subjects: 20
Study: 28735202

Group type: EXPERIMENTAL
Intervention: Wii Fit™ exercise therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no exercise therapy)
Number of subjects: 90
Study: 26416936

Group type: EXPERIMENTAL
Intervention: 6400 IU vitamin D3/day
Number of subjects: 334

Group type: COMPARATOR
Intervention: 400 IU vitamin D3/day
Number of subjects: 334
Study: 23666250

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Biomarkers related to inflammation (C-reactive protein, pentraxin 3, GDF-15, interleukin 6)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Biomarkers related to extracellular matrix remodelling (syndecan-1, periostin)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide, TNF-αR1a, GDF-15
Number of subjects: 567
Study: 21158922

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 53
Study: 18762944

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily plus calcium (1,000 mg) and vitamin D (800 IU)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control (daily alfacalcidol (1 microg) plus calcium (500 mg) for those with prevalent vertebral fractures; daily vitamin D (800 IU) plus calcium (1,200 mg) for those without previous vertebral fractures)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control
Number of subjects: 316
Study: 17786099

Group type: EXPERIMENTAL
Intervention: 40 mg controlled-release doxycycline
Number of subjects: 0
Study: 15042289

Group type: EXPERIMENTAL
Intervention: Naso-pharyngeal CPAP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hudson prongs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Infant Flow system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Naso-pharyngeal tube
Number of subjects: 40
Study: 11247106

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 9744511

Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin and vinblastine followed by surgery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined-modality treatment (chemotherapy and surgery)
Number of subjects: 31
Study: 7925789

Group type: EXPERIMENTAL
Intervention: Full vision of the hand and unrestricted movement of the eyes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No vision of the hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual fixation on a stationary LED
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral visual field target
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual pursuit of a second target moving at the same speed and direction
Number of subjects: 0
Study: 2839021

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 31412001

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 29419331

Group type: EXPERIMENTAL
Intervention: 10 Gy single fraction EBRT
Number of subjects: 112

Group type: COMPARATOR
Intervention: 20 Gy in five fractions EBRT
Number of subjects: 112
Study: 27250881

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (35 mg/m2, 6 cycles)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 weekly cisplatin (100 mg/m2, 3 cycles)
Number of subjects: 60
Study: 25269046

Group type: EXPERIMENTAL
Intervention: Lumbar Drainage (LD)
Number of subjects: 148

Group type: COMPARATOR
Intervention: External Ventricular Drainage (EVD)
Number of subjects: 148
Study: 21344320

Group type: EXPERIMENTAL
Intervention: Access to TV contingent on physical activity
Number of subjects: 30

Group type: COMPARATOR
Intervention: Free access to TV
Number of subjects: 30
Study: 19948879

Group type: EXPERIMENTAL
Intervention: Low-dose deferoxamine (2.5 mg/kg/week)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard-dose deferoxamine (5 mg/kg/week)
Number of subjects: 42
Study: 18608737

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg for 3 consecutive days, administered in three monthly pulses
Number of subjects: 57
Study: 15950634

Group type: EXPERIMENTAL
Intervention: TNF‐alpha plus infliximab (400 microg/mL)
Number of subjects: 31

Group type: COMPARATOR
Intervention: TNF‐alpha only
Number of subjects: 31
Study: 11809166

Group type: EXPERIMENTAL
Intervention: Event-related potential N270 in Parkinson's disease patients
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Event-related potential P300 in match condition
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (age-matched normal controls)
Number of subjects: 64
Study: 10582984

Group type: EXPERIMENTAL
Intervention: IV/IA r-TPA therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo/IA therapy
Number of subjects: 35
Study: 8688271

Group type: EXPERIMENTAL
Intervention: Taped message encouraging to stop smoking
Number of subjects: 363

Group type: COMPARATOR
Intervention: Blank tape
Number of subjects: 363
Study: 2053568

Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy
Number of subjects: 0
Study: 6140702

Group type: EXPERIMENTAL
Intervention: Withdrawal from long-term benzodiazepine treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 22
Study: 31600795

Group type: EXPERIMENTAL
Intervention: LV tissue Doppler MPI
Number of subjects: 79

Group type: COMPARATOR
Intervention: LV conventional spectral Doppler MPI
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: RV tissue Doppler MPI
Number of subjects: 79

Group type: COMPARATOR
Intervention: RV conventional spectral Doppler MPI
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: LV tissue Doppler MPI in obese subjects
Number of subjects: 79

Group type: COMPARATOR
Intervention: LV conventional spectral Doppler MPI in obese subjects
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: RV tissue Doppler MPI in obese subjects
Number of subjects: 79

Group type: COMPARATOR
Intervention: RV conventional spectral Doppler MPI in obese subjects
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intraobserver variability for LV conventional spectral Doppler
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 79
Study: 29845639

Group type: EXPERIMENTAL
Intervention: Benzocaine at 60, 85, 110, 135, and 160 mg/L
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Eugenol at 40, 80, 120, 160, and 200 mg/L
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Menthol at 50, 75, 150, 200, and 250 mg/L
Number of subjects: 75
Study: 26451499

Group type: EXPERIMENTAL
Intervention: PRF combined with autogenous anterior iliac crest bone graft
Number of subjects: 24

Group type: COMPARATOR
Intervention: Autogenous bone graft alone (control group)
Number of subjects: 24
Study: 24639242

Group type: EXPERIMENTAL
Intervention: HMB‐FA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HMB‐FA-CWI
Number of subjects: 40

Group type: COMPARATOR
Intervention: PL-CWI
Number of subjects: 40
Study: 22971253

Group type: EXPERIMENTAL
Intervention: Oral health counseling
Number of subjects: 99

Group type: COMPARATOR
Intervention: Traditional health education
Number of subjects: 99
Study: 21395142

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone, 6 mg/kg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral propafenone, 6.6 mg/kg/day
Number of subjects: 100
Study: 17270521

Group type: EXPERIMENTAL
Intervention: Whey and carbohydrate (CH(2)O) supplementation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Soy drink
Number of subjects: 3
Study: 16227697

Group type: EXPERIMENTAL
Intervention: Cefazolin (CEZ)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Ampicillin/sulbactam (SBT/ABPC)
Number of subjects: 157
Study: 12047205

Group type: EXPERIMENTAL
Intervention: Bed exercises in addition to standard post-operative mobilization protocol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard post-operative mobilization protocol (Control)
Number of subjects: 42
Study: 10354124

Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin (UH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin infusion
Number of subjects: 20
Study: 7749942

Group type: EXPERIMENTAL
Intervention: HHT (7.5% NaCl/10% HES 200)
Number of subjects: 23

Group type: COMPARATOR
Intervention: HES (0.9% NaCl/10% HES 200)
Number of subjects: 23
Study: 1702569

Group type: EXPERIMENTAL
Intervention: Amiksin (0.125-0.25 g orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiksin (1-2 tablets at least 2 days apart)
Number of subjects: 0
Study: 7460760

Group type: EXPERIMENTAL
Intervention: Methadone/methadyl acetate treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study: 31208714

Group type: EXPERIMENTAL
Intervention: Probiotics (Vivomixx® 1800 billion units/day) for 60 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Probiotics (Vivomixx® 1800 billion units/day) for 120 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 120 days
Number of subjects: 40
Study: 27810723

Group type: EXPERIMENTAL
Intervention: PTSD severity
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Previous suicide attempt
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Negative cognitions about the self and interpersonal support
Number of subjects: 366
Study: 25891753

Group type: EXPERIMENTAL
Intervention: Isokinetic training group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Isotonic training group
Number of subjects: 31
Study: 22720766

Group type: EXPERIMENTAL
Intervention: Directly observed fluoxetine treatment (once-weekly for 24 weeks, then self-administered for 12 weeks)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 137
Study: 21872629

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study: 19885996

Group type: EXPERIMENTAL
Intervention: Cort80 (6.3 mg/hr/70 kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cort160 (12.6 mg/hr/70 kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 36
Study: 17760727

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment with amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 20 mg b.i.d. for 14 days in patients with positive (13)C-UBT.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no H. pylori eradication treatment).
Number of subjects: 78
Study: 15172264

Group type: EXPERIMENTAL
Intervention: Preoperative intraaortic balloon pump (IABP) therapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no IABP)
Number of subjects: 133
Study: 11827603

Group type: EXPERIMENTAL
Intervention: Integrated-care program
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Computer-aided system
Number of subjects: 24
Study: 9725756

Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9065553

Group type: EXPERIMENTAL
Intervention: IVIg (2 g/kg intravenous immunoglobulin)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 19
Study: 1775594

Group type: EXPERIMENTAL
Intervention: d‐ala‐Peptide‐T‐amide (Peptide T) intravenous administration at doses ranging from 0.1 to 3.2 mg/kg/day for 12 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intranasal Peptide T at 25 mg/day for 8 weeks after a 4-week off-drug period
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control subjects (no drug administration)
Number of subjects: 14
Study: 7046652

Group type: EXPERIMENTAL
Intervention: Rifamycin SV, 500 mg weekly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline solution, 10 ml
Number of subjects: 30
Study: 29862630

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 100

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 100
Study: 28423038

Group type: EXPERIMENTAL
Intervention: Attentional bias training
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 137
Study: 26511489

Group type: EXPERIMENTAL
Intervention: Glucoraphanin (GFN) supplement providing Sulforaphane (SFN)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 25092356

Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy (MLE)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Lateral episiotomy (LE)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Both MLE and LE
Number of subjects: 563
Study: 22876876

Group type: EXPERIMENTAL
Intervention: Oxaliplatin/5-FU
Number of subjects: 201

Group type: COMPARATOR
Intervention: Oxaliplatin/capecitabine
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Infusional 5-FU
Number of subjects: 201

Group type: COMPARATOR
Intervention: Capecitabine based regimens
Number of subjects: 201
Study: 19615806

Group type: EXPERIMENTAL
Intervention: Emotional-writing condition
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Fact-writing condition
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Non-participants group (n=66)
Number of subjects: 148
Study: 17239882

Group type: EXPERIMENTAL
Intervention: Salvage autotransfusion
Number of subjects: 112

Group type: COMPARATOR
Intervention: Homologous blood transfusion
Number of subjects: 112
Study: 15128968

Group type: EXPERIMENTAL
Intervention: Education-about-violence program
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Combat stigma program
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study: 12638739

Group type: EXPERIMENTAL
Intervention: 2Hz EA
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2Hz TENS
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 100Hz TENS
Number of subjects: 13
Study: 9170595

Group type: EXPERIMENTAL
Intervention: Continuous sucking
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intermittent sucking
Number of subjects: 18
Study: 1438647

Group type: EXPERIMENTAL
Intervention: Imipramine (1 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4026972

Group type: EXPERIMENTAL
Intervention: Ethanol infusion to reach blood alcohol concentration of 1 mg/ml in 1 hr
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glucose infusion (control)
Number of subjects: 6
Study: 31997539

Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation (via the Optimizer System) plus standard of care (SoC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 3
Study: 29308539

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11083

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11083

Group type: EXPERIMENTAL
Intervention: Every SD increase in HGI
Number of subjects: 11083

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 11083
Study: 26651863

Group type: EXPERIMENTAL
Intervention: Exercise and Behavior Group (EBG)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Exercise Only Group (EG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 63
Study: 24423203

Group type: EXPERIMENTAL
Intervention: Roth prescribed edgewise bracket systems
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Damon 3MX bracket system
Number of subjects: 33
Study: 22042946

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4724

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4724
Study: 20529135

Group type: EXPERIMENTAL
Intervention: Antimuscarinic agents
Number of subjects: 0
Study: 18807574

Group type: EXPERIMENTAL
Intervention: Immediate loading of dental implants (20 implants)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed loading of dental implants (20 implants)
Number of subjects: 40
Study: 16076515

Group type: EXPERIMENTAL
Intervention: WHO partograph training and implementation by midwives
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no partograph training)
Number of subjects: 20
Study: 11799005

Group type: EXPERIMENTAL
Intervention: Two-portal technique
Number of subjects: 16

Group type: COMPARATOR
Intervention: Three-portal technique
Number of subjects: 16
Study: 10716066

Group type: EXPERIMENTAL
Intervention: Intranasal 17-beta-estradiol (300 microg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reservoir patch (50 microg/day of 17-beta-estradiol)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tablet (2 mg micronised 17-beta-estradiol)
Number of subjects: 36
Study: 8538478

Group type: EXPERIMENTAL
Intervention: Menorest 50 twice weekly for 12 weeks
Number of subjects: 214

Group type: COMPARATOR
Intervention: Premarin 0.625 mg daily for 12 weeks
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Menorest and Premarin
Number of subjects: 214
Study: 1985041

Group type: EXPERIMENTAL
Intervention: Psychological treatment (psychotherapy, relaxation, and standard medical treatment)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 102
Study: 6650773

Group type: EXPERIMENTAL
Intervention: Bovine carotid artery heterografts (BCAH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene grafts (PTFE)
Number of subjects: 0
Study: 30511258

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 19932

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19932
Study: 30451560

Group type: EXPERIMENTAL
Intervention: Peer support group intervention (8 weekly sessions of 1.5 hours each)
Number of subjects: 40
Study: 26817916

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Pre-MSH6 expression
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Post-MSH6 expression
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Tumor differentiation, postoperative chemotherapy, and pre-MSH6 expression
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: ypN category and perineural invasion
Number of subjects: 209
Study: 24534207

Group type: EXPERIMENTAL
Intervention: αTMS treatment group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham control group
Number of subjects: 46
Study: 21392832

Group type: EXPERIMENTAL
Intervention: Bone Marrow Stem Cells (BMSC) intracoronary infusion
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 20178593

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0